Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Shizue Nakagawa is active.

Publication


Featured researches published by Shizue Nakagawa.


Biochemical and Biophysical Research Communications | 1987

Expression of cDNA encoding human basic fibroblast growth factor in E. coli

Makoto Iwane; Tsutomu Kurokawa; Reiko Sasada; Masaharu Seno; Shizue Nakagawa; Koichi Igarashi

The cDNA encoding human basic fibroblast growth factor was expressed in E. coli under the control of trp promoter. Bacterially synthesized hbFGF was highly purified using a heparin affinity HPLC column. By this chromatography, hbFGF was eluted as four distinct forms, which were indistinguishable by SDS polyacrylamide gel electrophoresis, amino acid composition, and partial terminal sequence analysis. These molecules stimulated the growth of fibroblasts and endothelial cells although their specific activities varied. The angiogenesis activity of these molecules was also confirmed.


Diabetologia | 2001

The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats

Y. Nagisa; A. Shintani; Shizue Nakagawa

Aims/hypothesis. The results of the EUCLID trial (EURODIAB Controlled Trial of Lisinopril in Insulin-dependent Diabetes Mellitus) highlighted the importance of the renin-angiotensin system in the pathogenesis of diabetic retinopathy. Candesartan cilexetil (TCV-116), a potent angiotensin II (AII) receptor antagonist, has beneficial effects on hypertension as well as on heart, renal and cerebrovascular disease. We aimed to evaluate the effectiveness of candesarten cilexetil in ameliorating retinal disorders induced by hyperglycaemia. Methods. We compared retinal vascular endothelial growth factor (VEGF) mRNA expression and the latencies of retinal oscillatory potentials in TCV-116-treated and control groups of stroke-prone spontaneously hypertensive rats with streptozocin (STZ)-induced diabetes. Results. Retinal VEGF mRNA expression was significantly higher and the latencies of oscillatory potentials were significantly elongated in STZ-treated spontaneously hypertensive rats compared with a non-treated spontaneously hypertensive rat group matched for age. These changes were dependent on hyperglycaemia but independent of hypertension. Treatment with TCV-116 (3 mg/kg) significantly diminished retinal VEGF mRNA expression and the latencies of oscillatory potential peaks, but had no effect on plasma glucose concentrations. Conclusion/interpretation. These results suggest that TCV-116 is effective in preventing the development of diabetic retinopathy already in the early stages. [Diabetologia (2001) 44: 883–888]


Biochemical and Biophysical Research Communications | 1990

Production, purification and characterization of biologically active recombinant human nerve growth factor

Makoto Iwane; Yumiko Kitamura; Yoshihiko Kaisho; Koji Yoshimura; Asae Shintani; Reiko Sasada; Shizue Nakagawa; Kenji Kawahara; Kazuo Nakahama; Atsushi Kakinuma

The human NGF gene was isolated and inserted downstream from murine leukemia virus LTR in a plasmid having dihydrofolate reductase cDNA. The expression plasmid was introduced into CHO cells. Selection of the transformants for the resistance to methotrexate gave a CHO cell line which produced human NGF at a level of 4 mg/L in the culture medium. The recombinant human NGF was purified to near homogeneity from the culture supernatant. The NH2-terminal amino acid sequence, the COOH-terminal amino acid (Ala), and the amino acid composition of the human NGF were identical to those deduced from the nucleotide sequence of the human NGF gene. The recombinant human NGF was composed of 120 amino acid residues. Three disulfide linkages were determined to be Cys15-Cys80, Cys-58-Cys108, and Cys68-Cys110; the locations were identical to those in the mouse 2.5S NGF molecule. The specific biological activity of the recombinant human NGF was comparable with that of authentic mouse 2.5S NGF as determined by stimulation of neurite outgrowth from PC12 cells.


Molecular Immunology | 1986

Purification and characterization of IgE produced by human myeloma cell line, U266

Shuichi Ikeyama; Shizue Nakagawa; Arakawa M; Hiromu Sugino; Atsushi Kakinuma

Human IgE was isolated for the first time from the supernatant of the culture fluid of a human myeloma cell line, U266. The purification procedure consisted of salting out from the supernatant with ammonium sulfate, affinity chromatography on a lysine-Sepharose 4B column, ion exchange chromatography on a DEAE-Sephacel column, gel filtration and recycling chromatography on a Sephacryl S-300 column and removal of bovine proteins on an anti-bovine serum rabbit IgG-Sepharose 4B column. One hundred and twenty eight milligrams of IgE was recovered from 461 of culture fluid. The purification was extremely simplified by the introduction of immunoaffinity chromatography using the monoclonal antibody prepared by immunizing a mouse with an IgE preparation obtained by the above method: about 3.3 mg was recovered from 960 ml of culture fluid. The purified preparation was homogeneous as judged by the double-immunodiffusion test and end group analysis. The amino acid and carbohydrate compositions of the preparation coincided with those reported on other preparations obtained from the sera of myeloma patients. Our preparation, however, showed two bands with apparent mol. wts of 240,000 and 230,000 on sodium dodecyl sulfate polyacrylamide gel electrophoresis. When it was reduced with dithiothreitol and analyzed by electrophoresis, it gave two heavy chains and one light chain with apparent mol. wts of 80,000 and 76,000, and 28,000, respectively. On the other hand, the IgE molecule that was synthesized and secreted into the medium in the presence of tunicamycin (0.5 microgram/ml) gave only one heavy chain and one light chain with apparent mol. wts of 62,000 and 28,000, respectively. These results demonstrated that the two IgE molecular species contained in our preparation differed from each other in the carbohydrate moiety in their heavy chains.Abstract Human IgE was isolated for the first time from the supernatant of the culture fluid of a human myeloma cell line, U266. The purification procedure consisted of salting out from the supernatant with ammonium sulfate, affinity chromatography on a lysine-Sepharose 4B column, ion exchange chromatography on a DEAE-Sephacel column, gel nitration and recycling chromatography on a Sephacryl S-300 column and removal of bovine proteins on an anti-bovine serum rabbit IgG-Sepharose 4B column. One hundred and twenty eight milligrams of IgE was recovered from 461 of culture fluid. The purification was extremely simplified by the introduction of immunoaffinity chromatography using the monoclonal antibody prepared by immunizing a mouse with an IgE preparation obtained by the above method: about 3.3 mg was recovered from 960 ml of culture fluid. The purified preparation was homogeneous as judged by the double-immunodiffusion test and end group analysis. The amino acid and carbohydrate compositions of the preparation coincided with those reported on other preparations obtained from the sera of myeloma patients. Our preparation, however, showed two bands with apparent mol. wts of 240,000 and 230,000 on sodium dodecyl sulfate polyacrylamide gel electrophoresis. When it was reduced with dithiothreitol and analyzed by electrophoresis, it gave two heavy chains and one light chain with apparent mol. wts of 80,000 and 76,000, and 28,000, respectively. On the other hand, the IgE molecule that was synthesized and secreted into the medium in the presence of tunicamycin (0.5 μg/ml) gave only one heavy chain and one light chain with apparent mol. wts of 62,000 and 28,000, respectively. These results demonstrated that the two IgE molecular species contained in our preparation differed from each other in the carbohydrate moiety in their heavy chains.


Analytical Biochemistry | 1989

Direct amino acid analysis of proteins electroblotted onto polyvinylidene difluoride membrane from sodium dodecyl sulfate-polyacrylamide gel

Shizue Nakagawa; Tsunehiko Fukuda

The band of appropriate proteins (basic pancreatic trypsin inhibitor, soybean trypsin inhibitor, interleukin 2, and human leukocyte interferon alpha A) on a polyvinylidene difluoride (PVDF) membrane, which was electroblotted from sodium dodecyl sulfate (SDS)-polyacrylamide gel and then stained with Coomassie blue R-250, was cut out and directly hydrolyzed in HCl in the presence of thioglycolic acid for amino acid analysis. The analytical values agreed with those expected with recoveries of 29-47%, except that the value for tryptophan was very low or scarcely detected. This method was applied to the identification of human growth hormone (hGH) in a partially purified preparation. The amino acid composition of the band corresponding to about 2 micrograms of hGH agreed with the theoretical values. These results indicate that the band on the PVDF membrane can be directly hydrolyzed for amino acid analysis and that the method can be used for partially purified proteins separated using SDS-polyacrylamide gel electrophoresis.


Archive | 1999

Synthesis and biological activities of hPTH)1—34) analogues: modification of the middle part and C-terminal alkylamides

Junko Habashita; Shizue Nakagawa; Takumi Hamana; Masahiro Kawase; Shigehisa Taketomi; Tsunehiko Fukuda

Human parathyroid hormone (hPTH) is a peptide hormone, consisting of 84 amino acid residues, which regulates calcium and phosphate ion homeostasis. The N-terminal fragment, hPTH(1–34), has been shown to possess full biological activity. The hormone is thought to have promise in the treatment of bone diseases, including osteoporosis, because of the anabolic effect which is elicited by its intermittent administration. We have already reported the recombinant synthesis of hPTH(1–84) and hPTH(1–34) [1], as well as some structureactivity relationships concerned with the chemically synthesized analogues [2]. In the present study, various hPTH(1–34) analogues were synthesized by recombinant or Fmoc-based chemical methods, and the in vitro (cAMP production in MC3T3-E1 cells) and in vivo (bone growth stimulation in 4 week old male rats) activities were evaluated.


Archive | 1991

Parathyroid hormone derivatives

Shizue Nakagawa; Tsunehiko Fukuda; Masahiro Kawase; Iwao Yamazaki


Journal of Pharmaceutical Sciences | 2002

Prevention of bone loss in ovariectomized rats by pulsatile transdermal iontophoretic administration of human PTH(1–34)

Yasuyuki Suzuki; Yoshinori Nagase; Katsumi Iga; Masahiro Kawase; Masahiro Oka; Shigeo Yanai; Yukihiro Matsumoto; Shizue Nakagawa; Tsunehiko Fukuda; Hirotoshi Adachi; Naruhito Higo; Yasuaki Ogawa


Archive | 1996

Parathyroid hormone derivatives and their use

Tsunehiko Fukuda; Shizue Nakagawa; Junko Habashita; Shigehisa Taketomi


Journal of the American Chemical Society | 1994

Chemical Cleavage of Recombinant Fusion Proteins To Yield Peptide Amides

Shizue Nakagawa; Yuri Tamakashi; Takumi Hamana; Masahiro Kawase; Shigehisa Taketomi; Yoshihiro Ishibashi; Osamu Nishimura; Tsunehiko Fukuda

Collaboration


Dive into the Shizue Nakagawa's collaboration.

Top Co-Authors

Avatar

Tsunehiko Fukuda

Nagahama Institute of Bio-Science and Technology

View shared research outputs
Top Co-Authors

Avatar

Shigehisa Taketomi

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Masahiro Kawase

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Yasutaka Nagisa

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Hitoshi Ikeda

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Atsushi Kakinuma

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Iwao Yamazaki

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Junko Habashita

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Takao Yamada

Takeda Pharmaceutical Company

View shared research outputs
Researchain Logo
Decentralizing Knowledge